/CGEN

CGEN Stock - Compugen Ltd.

Q: What is the analyst price target for CGEN?

Analyst price target information is not currently available for CGEN.

Q: What is CGEN's market cap?

Market capitalization information is not currently available for CGEN.

Healthcare|Biotechnology|NASDAQ

$1.52+0.66%

+$0.01 (+0.66%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+184.9%upside

Target: $4.33

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CGEN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.83

52W High$2.66

52W Low$1.13

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$27.86M	$33.46M	$7.50M	$6.00M	$2.00M
Gross Profit	$19.93M	$31.45M	$6.53M	$5.32M	$1.94M
Gross Margin	71.5%	94.0%	87.0%	88.7%	97.0%
Operating Income	$-14,891,000	$-12,992,000	$-35,374,000	$-35,074,000	$-31,496,000
Net Income	$-14,231,000	$-18,754,000	$-33,694,000	$-34,203,000	$-29,698,000
Net Margin	-51.1%	-56.1%	-449.3%	-570.0%	-1484.9%
EPS	$-0.16	$-0.21	$-0.39	$-0.41	$-0.37

Company Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

Average Target

↑ 97.4% Upside

Now

Low

Average

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
January 13th 2025	Oppenheimer	Initiation	Outperform	$4
August 5th 2022	Jefferies	Downgrade	Hold	$2

Earnings History & Surprises

CGEN

Beat Rate

61%

Last 18 quarters

Avg Surprise

-5.3%

EPS vs Estimate

Beats / Misses

11/7

Last 12 quarters

Latest EPS

$-0.07

Q4 2025

EPS Surprise History

Q1 24

-52.2%

$0.11vs$0.23

Q2 24

+20.0%

$-0.08vs$-0.10

Q3 24

+75.0%

$-0.02vs$-0.08

Q4 24

-83.3%

$0.01vs$0.06

Q1 25

-200.0%

$-0.07vs$0.07

Q2 25

-33.3%

$-0.08vs$-0.06

Q3 25

-14.3%

$-0.08vs$-0.07

Q4 25

+22.2%

$-0.07vs$-0.09

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 18, 2026	—	—	—	—
Q1 2026	Mar 3, 2026	$-0.08	—	—	—
Q4 2025	Nov 10, 2025	$-0.09	$-0.07	+22.2%	✓ BEAT
Q3 2025	Aug 6, 2025	$-0.07	$-0.08	-14.3%	✗ MISS
Q2 2025	May 19, 2025	$-0.06	$-0.08	-33.3%	✗ MISS
Q1 2025	Mar 4, 2025	$0.07	$-0.07	-200.0%	✗ MISS
Q4 2024	Nov 12, 2024	$0.06	$0.01	-83.3%	✗ MISS
Q3 2024	Aug 6, 2024	$-0.08	$-0.02	+75.0%	✓ BEAT
Q2 2024	May 20, 2024	$-0.10	$-0.08	+20.0%	✓ BEAT
Q1 2024	Mar 5, 2024	$0.23	$0.11	-52.2%	✗ MISS
Q4 2023	Nov 7, 2023	$-0.09	$-0.11	-22.2%	✗ MISS
Q3 2023	Aug 7, 2023	$-0.13	$-0.11	+15.4%	✓ BEAT
Q2 2023	May 15, 2023	$-0.12	$-0.11	+8.3%	✓ BEAT
Q1 2023	Feb 27, 2023	$-0.14	$-0.04	+71.4%	✓ BEAT
Q4 2022	Nov 14, 2022	$-0.13	$-0.14	-7.7%	✗ MISS
Q3 2022	Aug 4, 2022	$-0.12	$-0.11	+8.3%	✓ BEAT
Q2 2022	May 16, 2022	$-0.12	$-0.11	+8.3%	✓ BEAT
Q1 2022	Feb 24, 2022	$-0.15	$-0.10	+33.3%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.13	$-0.07	+46.2%	✓ BEAT
Q3 2021	Jul 28, 2021	$-0.12	$-0.11	+8.3%	✓ BEAT